Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas-Reference-Cited by-同舟云学术

Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas

Published:2020-08-03 Issue:2 Volume:13 Page:94-98
ISSN:1874-4710
Container-title:Current Radiopharmaceuticals
language:en
Short-container-title:CRP

Author:

Bertagna Francesco¹,Albano Domenico¹,Cerudelli Elisabetta¹,Gazzilli Maria¹,Giubbini Raffaele¹,Treglia Giorgio²

Affiliation:

1. Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, Brescia, Italy

2. Department of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Bellinzona and Lugano, Switzerland

Abstract

Background: Radiolabeled prostate-specific membrane antigen PSMA-based PET/CT or PET/MRI is a whole-body imaging technique currently performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid tumors. Objective: The aim of this review is to evaluate the possible diagnostic role of radiolabeled PSMA PET/CT or PET/MRI in patients with gliomas and glioblastomas, by summarizing the available literature data. Methods: A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane library databases was conducted to find relevant published articles about the diagnostic performance of radiolabeled PSMA binding agents in PET/CT or PET/MRI imaging of patients with suspected gliomas or glioblastomas. Results: Seven case reports or case series and 3 studies enrolling more than 10 patients showed that gliomas and glioblastoma are PSMA-avid tumors. Conclusion: Radiolabeled PSMA imaging seems to be useful in analyzing glioma/glioblastoma. Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of radiolabeled PSMA in this setting and its possible position in the diagnostic flow-chart.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Radiology, Nuclear Medicine and imaging

Reference29 articles.

1. Treglia,G.; Annunziata,S.; Pizzuto, D.A.; Giovanella,L.; Prior, J.O.; Ceriani, L. Detection rate of 18F-Labeled PSMA PET/CT in biochemical recurrent prostate cancer: a systematic review and a meta-analysis. Cancers (Basel). 2019,11(5),E710 http://dx.doi.org/10.3390/cancers11050710 PMID: 31126071

2. Wu,H.; Xu,T.; Wang,X.; Yu, Y.B.; Fan, Z.Y.; Li, D.X.; Luo,L.; Yang, X.C.; Jiao,W.; Niu, H.T. Diagnostic performance of 68gallium labelled prostate-specific membrane antigen positron emission tomography/computed tomography and magnetic reso-nance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy: a systematic review and meta-analysis. World J. Mens Health. 2020,38(2),208-219. http://dx.doi.org/10.5534/wjmh.180124 PMID: 31081294

3. Perera,M.; Papa,N.; Roberts,M.; Williams,M.; Udovicich,C.; Vela,I.; Christidis,D.; Bolton,D.; Hofman, M.S.; Lawrentschuk,N.; Murphy, D.G. Ga llium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic u tility, sensitivity, specificity, and distribution of pros-tate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol. 2019, S0302-2838(19) 30095-8 http://dx.doi.org/10.1016/j.eururo.2019.01.049 PMID: 30773328

4. Afshar-Oromieh,A.; Avtzi,E.; Giesel, F.L.; Holland-Letz,T.; Linhart, H.G.; Eder,M.; Eisenhut,M.; Boxler,S.; Hadaschik, B.A.; Kratochwil,C.; Weichert,W.; Kopka,K.; Debus,J.; Haberkorn, U. The diagnostic value of PET/CT imaging with the (68) Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate can-cer. Eur, J. Nucl. Med. Mol. Imaging. 2015,42(2),197-209. http://dx.doi.org/10.1007/s00259-014-2949-6 PMID: 25411132

5. Kratochwil,C.; Giesel, F.L.; Eder,M.; Afshar-Oromieh,A.; Benešová, M.; Mier,W.; Kopka,K.; Haberkorn, U. [¹ 77Lu]Lutetium-labelled PSMA ligand-induced remission in a pa-tient with metastatic prostate cancer. Eur, J. Nucl. Med. Mol. Imag-ing. 2015,42(6),987-988. http://dx.doi.org/10.1007/s00259-014-2978-1 PMID: 25573634

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA PET in brain metastases: navigating diagnostic challenges– a thorough exploration;Clinical and Translational Imaging;2024-09-03

2. Prostate-Specific Membrane Antigen Use in Glioma Management;Clinical Nuclear Medicine;2024-07-03

3. Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals;Diagnostics;2024-05-13

4. The Utility of Prostate-Specific Membrane Antigen-11 PET in Detection and Management of Central Nervous System Neoplasms;Clinical Nuclear Medicine;2024-04-05

5. Comparison of PET/CT and PET/MRI in central nervous system tumors, a narrative review;International Journal of Physiology, Pathophysiology and Pharmacology;2024